title: Moderating effects and maintenance of lung cancer cellular immune functions by CIK cell therapy.
abstract: OBJECTIVE
  To study the CIK cell treatment effects on regulation of cellular immune function disorders in patients with lung cancer, and to analyze the time characteristics.
  
  
  METHODS
  Cellular immune function was assessed by FCM, and patients with functional disorders were randomly divided into two groups, one given CIK cell therapy within 18 months (5 courses) and the other the controls, which were followed up for 1 year with cellular immune functions tested once a month.
  
  
  RESULTS
  There were 5 types of cellular immunity, 4 of which are disorders; after CIK treatment, the improvement rate of the 4 groups were 79.1%, 70.8%, 76.0% and 70.0%, intergroup differences not being statistically significant (P=0.675), all significantly higher than in the control group (P=0.000). The median maintenance times for the 4 groups were 10.4 months (9.76-11.04), 8.4 months (7.86-8.94), 9.8 months (9.20-10.4) and 7.9 months (6.25-9.55), respectively.
  
  
  CONCLUSIONS
  CIK cells were able to improve the immune functions of patients with lung cancer, the rate of improvement and maintenance time being related to the immune function before the treatment and CIK-cell-therapy courses.
authors.affiliation: Cancer Research Institute of Yunnan Cancer Hospital, The 3rd Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, China. congguojin@yeah.net
authors.forename: Cong-Guo
authors.initials: CG
authors.lastname: Jin
authors.forename: Xiao-Qun
authors.initials: XQ
authors.lastname: Chen
authors.forename: Jia
authors.initials: J
authors.lastname: Li
authors.forename: Zhi-Pin
authors.initials: ZP
authors.lastname: Wu
authors.forename: Xin
authors.initials: X
authors.lastname: Liu
authors.forename: Xi-Cai
authors.initials: XC
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D064987:Cell- and Tissue-Based Therapy; D055612:Cytokine-Induced Killer Cells / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008168:Lung / Q000276:immunology*; D008175:Lung Neoplasms / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D015996:Survival Rate; D055815:Young Adult